Physician profile
Stacy Eagle
NPI 1003513144
$7,490.86
in general payments reported to CMS, 2019-2025
47 companies · $2,514 in 2025
The $2,514 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,192 · 2024: $2,785 · 2025: $2,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,316 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,315.86 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.52 | 2023-2025 | |
| Ucb, INC. | $504.97 | 2023-2025 | Briviact, Rystiggo, Fintepla |
| Lundbeck LLC | $419.46 | 2023-2025 | Vyepti, Rexulti |
| Pfizer INC. | $378.57 | 2023-2025 | |
| Neurelis, INC. | $358.34 | 2023-2025 | Valtoco |
| Biogen, INC. | $357.19 | 2023-2025 | Vumerity, Tysabri, Leqembi |
| Sk Life Science, INC. | $349.68 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $321.37 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $320.12 | 2024-2025 | Ultomiris |
| Lilly USA, LLC | $295.98 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Argenx US, INC. | $281.48 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $263.41 | 2024-2025 | Mavenclad |
| Scilex Pharmaceuticals INC. | $179.14 | 2023-2024 | Ztlido |
| Takeda Pharmaceuticals U.S.A., INC. | $153.41 | 2024-2025 | Hyqvia |
| Eisai INC. | $138.42 | 2024-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $128.32 | 2023-2024 | Nuedexta, Rexulti |
| Catalyst Pharmaceuticals, INC. | $123.90 | 2023-2025 | Fycompa |
| E.R. Squibb & Sons, L.L.C. | $121.98 | 2024 | Zeposia |
| Genentech USA, INC. | $119.31 | 2024-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Ipsen Biopharmaceuticals, INC | $119.23 | 2024-2025 | Dysport |
| Neurocrine Biosciences, INC. | $118.65 | 2023-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $117.82 | 2023-2024 | Inbrija |
| Mallinckrodt Hospital Products INC. | $113.09 | 2024-2025 | Acthar |
| Averitas Pharma INC. | $96.89 | 2024-2025 | Qutenza |
| Mdd US Operations, LLC | $94.24 | 2023 | Gocovri |
| Livanova USA, INC. | $92.93 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals Lp | $84.39 | 2024-2025 | Wainua |
| Amgen INC. | $73.46 | 2023-2025 | Uplizna, Aimovig |
| Alnylam Pharmaceuticals INC. | $72.81 | 2023 | Onpattro |
| Novartis Pharmaceuticals Corporation | $67.88 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $66.93 | 2023-2025 | Xeomin, Inbrija |
| Kyowa Kirin, INC. | $59.48 | 2023-2024 | Nourianz |
| Celgene Corporation | $53.57 | 2023 | Zeposia |
| Impel Pharmaceuticals INC. | $52.38 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $45.84 | 2023 | Lyvispah, Lioresal (Baclofen) |
| Tg Therapeutics, INC. | $45.23 | 2025 | |
| Corium, LLC | $43.24 | 2023 | Adlarity |
| Axsome Therapeutics, INC. | $41.04 | 2023 | Auvelity |
| Azurity Pharmaceuticals, INC. | $39.80 | 2023 | Horizant |
| Harmony Biosciences LLC | $39.03 | 2023 | Wakix |
| Csl Behring | $38.40 | 2024 | Hizentra |
| Janssen Biotech, INC. | $37.11 | 2025 | |
| Jazz Pharmaceuticals INC. | $29.32 | 2024-2025 | |
| Genzyme Corporation | $27.00 | 2025 | |
| Sumitomo Pharma America, INC. | $20.41 | 2024 | Aptiom |
| Acadia Pharmaceuticals INC | $18.93 | 2025 | Daybue |
| Ani Pharmaceuticals, INC. | $18.19 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Eagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.